There is a complex interplay between chronic kidney disease (CKD) and cardiovascular disease (CVD). The incidence of heart failure in this subpopulation increases with declining kidney function [1] . There is an overlap between the risk factors for CVD and CKD with both sharing the 'traditional' risk factors (age, hypertension, diabetes mellitus and dyslipidemia). In addition, there are 'nontraditional' risk factors specific to CKD (e.g. anemia, volume overload, metabolic abnormalities, proteinuria, malnutrition, oxidative stress and inflammation). Management of traditional risk factors has been shown to be ineffective in reducing the risk of cardiovascular events in CKD patients [2 & ]. Sixty-three percent of patients with CKD in the USA have CVD, as compared with 5.8% of those without CKD [3] . There is 50-fold increase in CVD mortality among dialysis patients (age 25-64). Patients on dialysis with baseline heart failure also have a poorer prognosis (median survival % 36 months) when compared with those not having heart failure at baseline (median survival % 62 months) [2 & ]. CVD prevalence also increases with increasing severity of CKD and a patient diagnosed with stage 3 CKD is at a higher risk of dying of CVD than of starting renal replacement therapy [3] .
In CKD, the predominant cardiac abnormality seems to be the dysfunction in the structure and function of the left ventricle (LV) [4] . This is due to the combination of coronary artery disease, myocardial hypertrophy, interstitial fibrosis, cardiomyocyte apoptosis and accumulation of extracellular matrix along with collagen. These structural changes result in increased LV stiffness, LV filling pressure and diastolic dysfunction, all of which contribute toward increased cardiac disease burden. One point of intervention for these patients is blood pressure control, but measurements obtained in clinic setting poorly reflect true values. One recent study looked at blood pressure control using ambulatory blood pressure monitoring (ABPM) versus office blood pressure measurements with a 5.2-year follow-up and found the adjusted risk of the composite cardiovascular outcome to be 3.2 times higher in the group of patients in whom office blood pressure was at goal but ABPM above goal when compared with the group of patients who had both office and ABPM readings at goal [5] .
Metabolic and hormonal derangements in CKD like hyperphosphatemia, accumulation of angiotensin II in the heart and elevated levels of serum aldosterone, all contribute to the cardiac dysfunction [6, 7] . Li et al. [8] have recently shown that the pulmonary hypertension in the presence of CKD also increases the risk of cardiac disease but not of cerebrovascular disease, whereas Torino et al. [9 & ] have shown that the risk of heart failure and mortality is increased in CKD patients who also demonstrated sleep-disordered breathing.
The treatment of CVD in CKD is aimed at reducing left ventricular hypertrophy, treating myocardial ischemia, addressing excess sympathetic nervous system activity and controlling reninÀ angiotensinÀaldosterone axis [10, 11] . Agarwal et al. [12 && ] have recently reported that b blockade is more effective than the inhibition of reninÀ angiotensin system in reducing the risk of cardiovascular events in patients on hemodialysis. In this study, both lisinopril and atenolol, given three times a week after hemodialysis, resulted in lowering left ventricular mass index, reducing cardiovascular events, hospitalizations for heart failure and all-cause hospitalizations. However, the beneficial effects were much more pronounced in the b blocker group in spite of attaining similar blood pressure targets (<140/90). One caveat of this study, though, is that majority of the study patients were fairly young and black.
In conclusion, there is emerging evidence to suggest that the approach to reduce CVD burden in CKD patients should be different to non-CKD patients [4, 8, 13 && ]. Further studies are warranted to understand the role of individual risk factors in detail thus leading to novel insights into the management of this complex problem. a Gladstone Centre, Diabetes Unit, Wrexham Maelor Hospital, Wrexham and b Countess of Chester NHS Foundation Trust, Chester, UK
